NCT06349434 The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function and ADL in Persons With SCI
| NCT ID | NCT06349434 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kessler Foundation |
| Condition | SCI - Spinal Cord Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-10-15 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-10-15 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the usefulness of an upper extremity assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury. The Department of Defense is supporting this study.
Eligibility Criteria
Inclusion Criteria: * Be between ages 18-80 * Be able to activate certain muscles in my arm and forearm on my own a sufficient amount as measured by EMG amplitude. This will be determined by the study OT/PT. * Be diagnosed with spinal cord injury (SCI) with level C1-C8 and ASIA Impairment Scale (AIS) C or D, as determined by study staff. If I have not had an exam to determine my injury level and impairment scale recently, I may participate in an examination of my sensation and strength in my arms, legs, trunk and rectum as was done in the hospital soon after my injury. * Be at least 1-year post injury * Have sufficient ability to move my shoulder (active shoulder flexion of 30 degrees and active shoulder abduction 20 degrees), as determined by study staff * Be medically stable * Have sufficient learning and memory abilities and abilities to communicate in English to be able to participate and follow directions during my rehabilitation * Continue to take all prescribed medication (e.g., oral or via pump baclofen) without any dosing changes * Be able to tolerate functional tasks for 60 minutes with periodic rests without excessive fatigue * Have minimal strength in the muscles that bend and straighten my elbow, as determined by study staff * Have full range of motion in my elbow when it is moved by the study therapist Exclusion Criteria: * Be younger than 18 years old or older than 80 * Have excessive pain in my arm, wrist, or hand that limits providing rehabilitation * Have excessive spasticity in my elbow or wrist, as determined by study staff * Be participating in any experimental rehabilitation or drug studies * Have history of nervous system disorder other than SCI * Have difficulty following multiple step directions * Have severe cognitive or psychiatric problems might be contraindications to start training. * Have skin issues or severe sensory deficits that would prevent wearing the Myo-Pro device safely * Be pregnant * Have other conditions or circumstances that, in the opinion of the investigators, would affect the safety or effectiveness of the training in which I would participate
Frequently Asked Questions
Who can join the NCT06349434 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying SCI - Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06349434 currently recruiting?
Yes, NCT06349434 is actively recruiting participants. Visit ClinicalTrials.gov or contact Kessler Foundation to inquire about joining.
Where is the NCT06349434 trial being conducted?
This trial is being conducted at West Orange, United States.
Who is sponsoring the NCT06349434 clinical trial?
NCT06349434 is sponsored by Kessler Foundation. The trial plans to enroll 60 participants.